Insider Trading Activity CymaBay Therapeutics (NASDAQ:CBAY) – CEO Bought 5,000 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For CymaBay Therapeutics (NASDAQ:CBAY)

Sujal Shah , CEO of CymaBay Therapeutics (NASDAQ:CBAY) reportedly Bought 5,000 shares of the company’s stock at an average price of 10.65 for a total transaction amount of $53,250.00 SEC Form

Insider Trading History For CymaBay Therapeutics (NASDAQ:CBAY)

On 5/15/2015 Charles Mcwherter, VP, bought 2,000 with an average share price of $3.16 per share and the total transaction amounting to $6,320.00.

On 5/18/2015 Wart Harold Van, CEO, bought 7,500 with an average share price of $3.34 per share and the total transaction amounting to $25,050.00.

On 5/18/2015 Sujal Shah, CFO, bought 10,000 with an average share price of $3.40 per share and the total transaction amounting to $34,000.00.

On 7/20/2015 Emster Kurt Von, Director, bought 1,600,000 with an average share price of $2.81 per share and the total transaction amounting to $4,496,000.00.

On 8/14/2015 Emster Kurt Von, Director, bought 90,000 with an average share price of $2.69 per share and the total transaction amounting to $242,100.00.

On 9/11/2015 Carl Goldfischer, Director, sold 46,729 with an average share price of $2.74 per share and the total transaction amounting to $128,037.46.

On 4/4/2016 Sujal Shah, CFO, bought 22,000 with an average share price of $1.39 per share and the total transaction amounting to $30,580.00.

Analyst Ratings History For CymaBay Therapeutics (NASDAQ:CBAY)

On 7/20/2017 Citigroup Reiterated Rating Outperform with a price target of $8.00 ➝ $15.00
On 7/20/2017 CIBC Reiterated Rating Outperform ➝ Outperform with a price target of $8.00 ➝ $15.00
On 8/11/2017 Ifs Securities Downgraded rating Strong-Buy ➝ Outperform
On 1/25/2018 Roth Capital Reiterated Rating Buy ➝ Buy with a price target of $27.00
On 2/13/2018 Evercore ISI Initiated Coverage of rating Outperform ➝ Outperform
On 3/16/2018 Cantor Fitzgerald Reiterated Rating Buy with a price target of $16.00
On 3/16/2018 Piper Jaffray Reiterated Rating Buy with a price target of $16.00

Recent Trading Activity for CymaBay Therapeutics (NASDAQ:CBAY)
Shares of CymaBay Therapeutics closed the previous trading session at 11.75 up +0.08 0.69% with 11.75 shares trading hands.